{"nctId":"NCT01444092","briefTitle":"Safety Study of Entocort for Children With Crohn's Disease","startDateStruct":{"date":"2011-11"},"conditions":["Crohn's Disease"],"count":123,"armGroups":[{"label":"Entocort","type":"EXPERIMENTAL","interventionNames":["Drug: Entocort"]}],"interventions":[{"name":"Entocort","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* All male and female subjects must be aged 5 to 17, inclusive, and must not have reached their 18th birthday by the estimated final office visit.\n* Subject must be diagnosed with active Crohn's disease of the ileum and/or ascending colon confirmed by endoscopic and/or radiographic evidence, and/or evidence of mucosal erosions and/or histology.\n* Subjects with mild to moderate Crohn's disease.\n* All subjects must have a stool analysis negative for Clostridium difficile toxin, Yersinia enterolytica, Campylobacter jejuni, Salmonella, Shigella, within the 30 days prior to visit 1.\n* All subjects must have had laboratory assessments within 7 days prior to visit 1.\n* All subjects must weigh \\>= 15 kg at time of enrollment\n\nExclusion Criteria:\n\n* Subjects who have had any previous intestinal resection proximal to and including the ascending colon\n* Subjects with evidence of severe active Crohn's disease and/or, stricturing and prestenotic dilatation, clinical evidence of obstruction, perirectal abscess, perirectal disease with active draining fistulas, perforation, or any septic complications\n* Subjects who do not have a negative stool analysis, within the 30 days prior to visit 1\n* Subjects who have been screened/or enrolled in this study previously within the last 30 days\n* Subjects with morning cortisol level \\<150 nmol/l (5.4 ug/dl) or DHEA-S below normal range for age and gender","healthyVolunteers":false,"sex":"ALL","minimumAge":"5 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Adverse Event","description":"Number of patients with at least one adverse event","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79","spread":null}]}]}]},{"type":"SECONDARY","title":"PCDAI","description":"Paediatric Crohn's Disease Activity Index. Range from 0 (best) to 100 (worst).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.10","spread":"10.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.0","spread":"10.1"}]}]}]},{"type":"SECONDARY","title":"IMPACT 3","description":"IMPACT 3 is a self-administered QoL form. The score ranges from 35 (poor) to 175 (best).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"132.1","spread":"18.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.8","spread":"13.3"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":108},"commonTop":["Increased appetite","Abdominal pain","Acne","Irritability","Cushingoid"]}}}